The Unity trial presented at the ANRS MIE 2025 Scientific Days

The ANRS Emerging infectious diseases 2025 Scientific Days were held on 1 and 2 April 2025 in Paris, France. This conference was an opportunity for Alexandra Calmy (University Hospitals of Geneva, Switzerland) to present the Unity trial to an audience of scientists, associations and decision-makers.

Alongside her, Placide Mbala (INRB, University of Kinshasa, Democratic Republic of the Congo) presented the provisional results of the Palm 007 trial, which aims to randomly evaluate the antiviral drug tecovirimat against monkeypox in the Democratic Republic of the Congo.

The Unity trial, a model of adaptability in epidemic situations.

The Unity clinical trial is a randomised controlled study evaluating the efficacy and safety of tecovirimat in patients with confirmed mpox infection. The study is unique in that it was deployed in the context of a global health emergency, immediately after the WHO declared a public health emergency of international concern in July 2022. Its implementation required an exceptional level of responsiveness in the face of a disease that is still largely unknown, both in terms of its clinical expression and its evolution and potential complications.

Based on the WHO Master Protocol, the Unity trial has had to meet a number of challenges, particularly in terms of governance and adaptability, in a constantly changing medical landscape. It has required ongoing reassessment of its methodologies, incorporating new data from parallel research on tecovirimat.

The study is ongoing, and the first results are expected in 2025.

Find all presentations from the 2025 Scientific Days on the ANRS MIE Youtube channel.